223
Participants
Start Date
April 30, 2020
Primary Completion Date
January 14, 2021
Study Completion Date
January 2, 2022
Remestemcel-L
administered twice during the first week, with the second infusion at 4 days following the first injection (± 1 day)
Placebo
administered twice during the first week, with second infusion at 4 days following the first injection (± 1 day)
New York University Langone Health, New York
Mount Sinai Health, New York
Northwell Health, New York
University of Pennsylvania Health System, Philadelphia
University of Maryland, Baltimore
University of Virginia, Charlottesville
WakeMed, Raleigh
Duke University Medical Center, Durham
Emory University, Atlanta
Cleveland Clinic Foundation, Cleveland
Lutheran Hospital, Fort Wayne
University of Michigan, Ann Arbor
Ochsner Clinic, New Orleans
Baylor, Smith & White, Plano
Houston Methodist Hospital, Houston
Dignity Health, Gilbert
University of Southern California, Los Angeles
Stanford University, Stanford
Maine Medical Center, Portland
Brigham and Women's Hospital, Boston
Dartmouth-Hitchcock, Lebanon
Collaborators (1)
Mesoblast, Inc.
INDUSTRY
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Icahn School of Medicine at Mount Sinai
OTHER